BFUHS to Close NEET PG Round 3 Counselling 2024 Choice-Filling Window Today

Punjab- Baba Farid University of Health Sciences (BFUHS) is going to close the National Eligibility and Entrance Test-Postgraduate (NEET PG) Round 3 counselling choice-filling process for the academic year 2024-25 today. Registered candidates can access the Punjab NEET PG Round 3 Counselling 2024 choice-filling window through the official website of BFUHS.

As per the schedule, candidates including NRI candidates who have submitted their willingness for the 3rd round can fill/submit the online options/preferences of speciality/college from the 29th to today i.e. 30th January 2024.

Also Read: BFUHS Revises NEET PG Round 3 Counselling Schedule, Check Details

Following this, BFUHS will start the Punjab NEET PG Round 3 counselling 2024 seat allotment process from tomorrow i.e., January 31, 2025, to February 02, 2025. Punjab NEET PG 2024 Round 3 seat allotment will be based on the candidate’s rank, category, preferences filled during choice locking and seat availability in the respective institutes.

After the completion of the seat allotment process, the result will be declared on February 02, 2025. With this, candidates will also be allowed to raise objections, if any, against the Punjab NEET PG 2024 round 3 seat allotment result. However, to raise an objection, candidates will be required to submit the following required documents through email.

DOCUMENTS

1 Class 10 certificate

2 MBBS degree

3 Bank draft

4 NEET PG result

5 Scan of full signature as used during NEET PG registration

6 Print out a duly filled and signed online application form

7 Updated medical registration certificate

8 Permanent resident certificate

9 Service certificate (if applicable)

10 Authorization letter (if applicable)

11 MBBS mark sheet

12 Internship completion certificate

13 Scan of passport size photograph of the candidate as submitted in the NEET PG application form

14 Category certificate (if applicable).

Meanwhile, if there is any change in provisional allotment after considering objections and after weeding out the joined candidates from the data shared by MCC, the final provisional result will be displayed through the university website on 06th February 2025.

Also Read: NEET PG- Hind Institute of Medical Sciences lowers fee for Non-Clinical Depts, check details

Powered by WPeMatico

FDA approves Semaglutide for renal protection among diabetes patients with CKD

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular-related death in adults with type 2 diabetes and chronic kidney disease (CKD), making it the only GLP-1 receptor agonist with this indication.

This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart disease, establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class.

“Chronic kidney disease is very serious and common in patients living with type 2 diabetes and represents a critical need for adults living with these comorbidities. This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated,” said Anna Windle, PhD, Senior Vice President Clinical Development, Medical & Regulatory Affairs at Novo Nordisk. “With this new indication, Ozempic stands out uniquely as the most broadly indicated GLP-1 RA in its class. We are proud to continue advancing innovations that will have a meaningful impact for this patient population, underscoring Novo Nordisk’s commitment to cardiometabolic care.”

CKD affects approximately 37 million adults in the U.S. and is expected to rise with an aging demographic and increasing prevalence of diabetes, the leading cause of CKD and kidney failure. CKD is a common complication of type 2 diabetes, with approximately 40% of people with type 2 diabetes also experiencing CKD. For people with type 2 diabetes, CKD can be a significant burden and can cause additional sickness, including increased risk of cardiovascular problems and death.

This FDA approval is based on results from the FLOW phase 3b kidney outcomes trial investigating the effects of once-weekly Ozempic injection on major kidney and cardiovascular outcomes in adults with type 2 diabetes and CKD.1 The FLOW trial achieved its primary endpoint with Ozempic 1 mg, demonstrating a statistically significant and superior 24% relative risk reduction of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease (4.9% absolute risk reduction at 3 years) compared to placebo, when added to standard of care.

“Type 2 diabetes can be challenging enough to manage without the added risk of chronic kidney disease, and I have seen in my own practice that patients with type 2 diabetes and chronic kidney disease need extra support from medications that may have a profound clinical impact by lowering the risk of major kidney and cardiovascular outcomes,” said Richard E. Pratley, MD, Medical Director at the AdventHealth Diabetes Institute Orlando, FL, and Co-Chair of the FLOW Trial. “A large portion of patients I treat experience serious kidney complications and comorbidities, with some even requiring dialysis. Today’s decision by the FDA offers hope for the millions of adults living with both conditions and provides an additional treatment option, representing a significant advancement for my patients.”

The FDA initially approved Ozempic in 2017 to improve blood sugar (glucose), along with diet and exercise, in adults with type 2 diabetes. In 2020, Ozempic was granted an additional indication to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease. Today, the FDA has expanded the benefits of Ozempic to a new patient population that needs critical treatment options to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic.

About FLOW

FLOW was an international, randomized, double-blind, parallel-group, placebo-controlled, event-driven superiority trial comparing once-weekly Ozempic 1 mg with placebo as an adjunct to standard of care on kidney outcomes for reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥50%, sustained eGFR < 15 mL/min/1.73 m2, chronic renal replacement therapy, renal death, and CV death in adults with type 2 diabetes and CKD. 3,533 adults (1,767 in the Ozempic group and 1,766 in the placebo group) were enrolled in the trial conducted in 28 countries at approximately 400 investigator sites. The FLOW trial was initiated in 2019. At the recommendation from an Independent Data Monitoring Committee, the FLOW study was stopped early due to meeting pre-specified efficacy criteria after a median follow-up of 3.4 years.

What is Ozempic

Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:

• along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes

• to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease

• to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease

It is not known if Ozempic is safe and effective for use in children.

Powered by WPeMatico

Oxidized HDL Increase Risk of Heart Failure with Preserved Ejection Fraction: Study

A recent study published in the Clinical Research in Cardiology journal linked impaired high-density lipoprotein (HDL) function to an increased risk of heart failure with preserved ejection fraction (HFpEF). The study highlights the critical role of oxidative stress and inflammation in the pathophysiology of HFpEF by emphasizing the significance of oxidized HDL (nHDLox).

This research analyzed the HDL antioxidant function in 366 patients with suspected heart failure, including 88 diagnosed with HFpEF. The antioxidant function of HDL was assessed using a validated cell-free biochemical assay. By measuring the lipid peroxide content of HDL (HDLox) normalized by HDL cholesterol levels (HDL-C) and comparing it with control values from healthy participants, this study identified a clear association between increased nHDLox levels and HFpEF.

The key findings revealed that patients with HFpEF had, on average, 15% higher levels of nHDLox when compared to participants without heart failure. These elevated levels of oxidized HDL suggest diminished antioxidant function in HFpEF patients. Also, even after adjusting for variables like age, sex, kidney function, diabetes, hypertension, atrial fibrillation, and other cardiovascular risk factors, nHDLox remained an independent predictor of HFpEF.

Every standard deviation (SD) increase in nHDLox was associated with a 67% greater risk of HFpEF when compared to the individuals without heart failure. These findings underline the potential of nHDLox as a biomarker for early detection of HFpEF and emphasize its importance in guiding future therapeutic strategies.

HFpEF, is a heterogeneous clinical syndrome with limited treatment options. Current approaches primarily focus on symptom management rather than targeting the underlying causes. The discovery of impaired HDL antioxidant function as a risk factor opens new avenues for addressing HFpEF through early intervention.

Overall, the findings of this research suggest that restoring or improving HDL function could serve as a promising therapeutic target. Strategies to reduce oxidative stress and inflammation may hold the key to reduce the progression of HFpEF. While further studies and trials are needed to explore the mechanisms and treatment possibilities, this research provides a significant step forward in understanding the complex biology of heart failure.

Reference:

Sasko, B., Kelesidis, T., Kostin, S., Scharow, L., Mueller, R., Jaensch, M., Wintrich, J., Christ, M., Ritter, O., Ukena, C., & Pagonas, N. (2025). Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. https://doi.org/10.1007/s00392-024-02583-3

Powered by WPeMatico

Age, gender, and method of catheter implantation influence Inflow and Drain Pain After Peritoneal Dialysis: Study

Researchers have found in a new study that the occurrence of inflow pain and drain pain following peritoneal dialysis catheter implantation is notable. A recent study identified age, gender, and the method of catheter implantation as independent factors influencing the incidence of inflow or drain pain within the first postoperative week. These findings highlight the importance of considering patient-specific factors to optimize post-implantation pain management.

The high prevalence and prolonged duration of inflow pain and drain pain experienced by peritoneal dialysis (PD) patients following PD catheter implantation impacts their quality of life. However, there is limited data on the frequency and predisposing factors of these pains in the Chinese population undergoing peritoneal dialysis. This study encompassed individuals who underwent peritoneal dialysis catheter implantation at the institution from September 1, 2023, to March 31, 2024.

Patients’ experiences of inflow pain and drain pain were evaluated using a questionnaire survey and the visual analogue scale (VAS), with pain status followed up via telephone for 3 months post-surgery. Results A total of 141 patients were included in this study. Inflow pain occurred at rates of 56.0%, 20.9%, 16.9%, and 17.3% at 1-week, 1-month, 2-month, and 3-month postoperatively, respectively, while drain pain rates were 51.8%, 24.3%, 22.3%, and 19.5% for the same period. Slowing down the infusion rate of dialysate (57.0%) or stopping its drainage (60.3%) proved effective in reducing pain. Logistic regression analysis revealed that age (OR=0.96, P=0.02), gender (OR=0.37, P=0.03), and the method of PD catheter implantation (OR=2.37, P=0.04) were independent factors associated with inflow or drain pain within 1-week postoperatively.

The occurrence of inflow pain and drain pain following peritoneal dialysis catheter implantation is notable. Age, gender, and the method of catheter implantation were identified as independent factors influencing the incidence of inflow or drain pain within the first postoperative week.

Reference:

Kim, D.-H., & Han, G.-S. (2025). Periodontitis as a risk factor for dementia: A systematic review and meta-analysis. Journal of Evidence-Based Dental Practice, In Press. https://doi.org/10.1016/j.jebdp.2025.102094

Powered by WPeMatico

Taking blood pressure in public or noisy settings does not affect reading, suggests study

A randomized crossover trial found minimal difference between blood pressure (BP) readings obtained in public spaces versus those taken in private offices. These findings suggest that public spaces can be an acceptable setting for BP screenings, despite prior clinical guideline recommendations advising quiet settings for BP measurement. The results are published in Annals of Internal Medicine.

Researchers from Johns Hopkins University randomly assigned 108 adults in Baltimore, MD to the order in which they had triplicate BP measurements in each of 3 settings: 1) private quiet office (private quiet [reference]); 2) noisy public space (public loud); and 3) noisy public space plus earplugs (public quiet) to evaluate the effect of noise and public environment on BP readings. The primary outcomes were differences between the mean BPs obtained in each public setting with those obtained in the private setting. The average noise level in the private quiet setting was 37 decibels (dB) and the average noise level in the public setting was 74 dB. In the private quiet setting, the average systolic BP (SBP) and diastolic BP (DBP) were 128.9 and 74.2 mm Hg, respectively. In the public loud setting, the mean SBP and DBP were 128.3 and 75.9 mm Hg and in the public quiet setting, the mean SBP and DPB were 129.0 and 75.7 mm Hg.

The results indicate that the differences in BP readings in public, loud spaces versus the clinically recommended setting of a private office are small and not clinically significant. The researchers say these results support the implementation of mass hypertension-screening programs in settings including supermarkets, places of worship and schools.   

Reference:

Junichi Ishigami, Hairong Liu, Di Zhao, et al. Effects of Noise and Public Setting on Blood Pressure Readings: A Randomized Crossover Trial. Ann Intern Med. [Epub 28 January 2025]. doi:10.7326/ANNALS-24-00873.

Powered by WPeMatico

Thyroid Function Alterations Linked to Respiratory Allergies, study shows

Researchers have found that thyroid function has a significant role in the complex interplay between metabolic, endocrine, and immune responses in respiratory allergy patients, such as those with allergic rhinitis and asthma. The study was conducted by Lokaj-Berisha and fellow researchers published in the journal Scientific Reports.

Allergic rhinitis and asthma have multifactorial etiologies involving specific genetic predispositions, environmental exposures, and the immune response. Other less-known factors that may be involved are related to thyroid function. This study aimed to examine the correlation between respiratory allergy and serum levels of thyroid hormones in 66 allergic rhinitis patients, 20 suffering concomitantly from asthma, and 30 controls without these symptoms.

Participants were evaluated for BMI, serum IgE, and thyroid hormone levels, including T3, T4, and TSH. Skin prick tests were done to assess the sensitivity of participants to allergens, and a family history of atopy was noted. Pearson correlation analysis was applied to evaluate the relationship between age, BMI, thyroid hormones, and sex-specific differences.

Key Findings

  • Participant Demographics: The mean age of the participants is 29.55 years. Out of the participants, 66.4% have a family history of atopy.

  • Allergen Sensitivities : Skin prick test showed that house dust mites are the most common cause of allergy with 55.2% sensitivity.

  • Serum IgE Levels: Patients with respiratory allergies also had significantly higher serum IgE levels (mean = 36.85 IU/mL) among the patients with both allergic rhinitis and asthma (mean = 218 IU/mL).

  • Thyroid Hormone Differences: There was a statistically significant difference between the groups concerning serum T4 levels in allergic rhinitis (p< 0.001 and p<0.05).

  • Metabolic and Endocrine Correlations: The correlation analysis revealed correlations between age, BMI, and thyroid hormones and showed sex-specific differences (p<0.05 and p<0.01).

  • BMI was within normal limits in all study groups, meaning that there is no direct metabolic abnormality with regard to thyroid function or respiratory allergies.

This study illustrates that alterations in thyroid function are significantly associated with respiratory allergies, especially in males. The endocrine, metabolic, and immune systems interactions may become potential targets for therapeutic interventions. Further research would be required to study the underlying mechanisms and develop personalized treatments for the individuals affected.

Reference:

Lokaj-Berisha, V., Gacaferri Lumezi, B. Increased thyroxine levels of patients with allergic rhinitis. Sci Rep 15, 2667 (2025). https://doi.org/10.1038/s41598-025-85762-0

Powered by WPeMatico

Oral Antibiotics Noninferior to IV Treatment for Fracture-Related Infections: JAMA

USA: The management of fracture-related infections (FRIs) often involves prolonged antibiotic therapy, with intravenous (IV) administration traditionally being the standard. However, recent findings from the POvIV Randomized Clinical Trial offer compelling evidence that oral antibiotics may be a viable alternative to IV therapy in certain cases, potentially simplifying treatment protocols and improving patient convenience.

The authors revealed that oral antibiotic treatment was noninferior to intravenous treatment concerning the primary outcome, the number of surgical interventions, as determined by the mITT analysis. However, the researchers noted some uncertainty in these findings based on the results of preplanned and post hoc secondary analyses. A similar trend in treatment effect estimates was observed for the secondary outcome, which evaluated the recurrence of infection. The findings were published online in JAMA Surgery.

Fracture-related infection is a significant complication following fracture fixation surgery, often requiring debridement and a six-week course of IV antibiotics as the standard treatment. While IV antibiotics have been the traditional approach, laboratory data, and retrospective clinical studies suggest that oral antibiotics could be an effective alternative, offering advantages such as lower costs and potentially fewer complications.

Against this backdrop, William T. Obremskey, MD, MPH, MMHC, Vanderbilt University Medical Center, Nashville, TN, and colleagues from the Major Extremity Trauma Research Consortium (METRC), aimed to evaluate the effectiveness of oral antibiotics compared to IV antibiotics in the treatment of FRIs, providing evidence to inform future clinical decision-making.

For this purpose, the researchers conducted the POvIV multicenter, prospective randomized clinical trial across 24 trauma centers in the US, enrolling patients aged 18 to 84 years with fracture repair or arthrodesis involving implants who developed fracture-related infections (FRIs) without radiographic evidence of osteomyelitis. Patients were followed for 12 months after hospitalization between March 2013 and September 2018.

The trial compared oral and intravenous (IV) antibiotics. The primary outcome was the number of study injury-related surgical interventions within a year. Secondary outcomes included the recurrence of deep surgical site infections, which were analyzed using preplanned and post hoc methods to ensure reliability.

The following were the key findings of the study:

  • The study included 233 patients with a mean age of 46.0 years, and 22.7% of patients were female.
  • The mean number of surgical interventions within one year was 1.3 for the oral group and 1.1 for the IV group.
  • The upper bound of the 95% confidence interval for the mean difference in the unadjusted mITT analysis was 0.59, which was below the prespecified noninferiority margin of 0.67, suggesting noninferiority of oral to IV antibiotics.
  • The adjusted PP analysis did not support the noninferiority of the number of reoperations.
  • A post hoc adjusted mITT analysis indicated noninferiority.
  • The treatment effect estimates for reinfection, a key secondary outcome, followed a similar pattern to the primary outcome.

The POvIV randomized clinical trial demonstrates that oral antibiotics are noninferior to IV antibiotics for the primary outcome of surgical interventions based on mITT analyses. However, oral antibiotics did not show noninferiority in the secondary PP analysis. While reinfection rates were similar in the unadjusted mITT analysis, adjusted mITT and PP analyses revealed greater differences.

“These findings can assist clinicians and patients in making informed decisions about antibiotic care for FRIs,” the researchers concluded.

Reference:

Major Extremity Trauma Research Consortium (METRC). Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial. JAMA Surg. Published online January 22, 2025. doi:10.1001/jamasurg.2024.6439

Powered by WPeMatico

Sunscreen, serum, and cleanser regimen improved cosmetic aspects of skin with acne vulgaris, suggests study

A new study published in the Journal of Drugs in Dermatology showed that adults with acne responded well to a regimen that included a broad-spectrum sunscreen, balancing serum, and clarifying cleanser. One of the most common dermatological conditions, acne vulgaris which is a chronic inflammatory pilosebaceous skin disorder that affects the face, chest, and back. It affects approximately 85% of people, with young adolescents being particularly affected.

Acne is linked to increased sebum production by overactive oil glands, hyperkeratinization by blocking skin pores, the subsequent release of skin inflammatory mediators, and bacterial colonization in the follicles that results in the carrying of commensal skin microorganisms. 3 main gram-positive bacteria are involved in the bacterial colonization of the follicle which are Cutibacterium acnes (formerly Propionibacterium acnes), Staphylococcus epidermidis, and Staphylococcus aureus.

Acne vulgaris is often treated with anti-acne medicines such as retinoic acid and derivatives, azelaic acid, salicylic acid, benzoyl peroxide, vitamins B and C, and antibiotics such as tetracyclines and macrolides like clindamycin. However, persistent use of these chemical-based medicines may result in tinnitus, lightheadedness, dizziness, and skin irritation.

There are several over-the-counter acne treatments available, but many of the formulations have problems with tolerability and do not have the sophisticated appearance that adult patients want. Thereby, assessing the effectiveness and acceptability of an active, non-prescription acne treatment regimen in adult patients with all Fitzpatrick skin types was the main goal of this study.

This 8-week, single-site, monadic research included a total of 35 male and female participants with Fitzpatrick skin types I to VI. A clarifying cleanser, balancing serum, and broad-spectrum sunscreen were all part of the acne treatment plan. These products were made with components that worked in concert to minimize acne and post-acne symptoms including post-inflammatory erythema (PIE) and post-inflammatory hyperpigmentation (PIH).

The reduction of inflammatory lesions by 63%, non-inflammatory lesions by 41%, and investigator overall evaluation by 51% was statistically significant after 8 weeks of administration. Furthermore, there was a notable increase in skin softness, brightness, tactile smoothness, and visual smoothness.

The severity of post-acne sequelae, such as PIH and PIE, improved by 27%. The individuals rated the tolerability of this regimen as excellent. Also, 78.5% of participants concurred that their skin looked healthier and more luminous after using the product for 8 weeks.

A well-formulated, cosmetically appealing active acne regimen was shown to be extremely effective and well tolerated by adult acne patients of various ethnicities. Overall, the routine improved esthetic features of the skin, such as PIH and PIE, which are significant in treating adult acne patients.

Source:

Farris, P. K., Gerstein, F. H., Harper, J. C., & Draelos, Z. D. (2024). Effective With Minimal Side Effects: A Novel Treatment Regimen for Acne Vulgaris Using Multifunctional Ingredients. In Journal of Drugs in Dermatology (Vol. 23, Issue 12, pp. 1042–1048). SanovaWorks. https://doi.org/10.36849/jdd.8458

Powered by WPeMatico

Younger Age at Cataract Surgery Increases Glaucoma Risk; Glaucoma Valve Implantation Outperforms Trabeculectomy, Study Finds

China: Recent findings published in International Ophthalmology highlight key factors associated with the onset of glaucoma-related adverse events (GRAE) in children following pediatric cataract surgery. The study revealed that undergoing pediatric cataract surgery at a younger age significantly raises the risk of early-onset GRAE, especially in children under six months, who are most vulnerable.

“In evaluating different surgical options, glaucoma valve implantation emerged as the preferred choice, demonstrating a notably lower re-operation rate of 12.1%, compared to 50% for trabeculectomy. This positions glaucoma valve implantation as a more effective solution for managing intraocular pressure (IOP) in these pediatric patients,” the researchers reported.

Glaucoma valve implantation involves the placement of a drainage device to regulate intraocular pressure, and in children with GRAE, this procedure can provide long-term control of glaucoma. Na Wu & Xinghuai Sun from Shanghai Medical College in Fudan University, Shanghai, China, aimed to outline the clinical characteristics of glaucoma-related adverse events following pediatric cataract surgery. It also sought to identify the factors influencing the timing of GRAE onset and determine the preferred surgical approach for managing these glaucoma complications.

For this purpose, the researchers retrospectively reviewed hospitalized medical records of patients who developed GRAE, including glaucoma and glaucoma suspects, following pediatric cataract surgery (performed at or before 14 years of age) between 1994 and 2021. If the interval between cataract surgery and the diagnosis of GRAE was less than one year, the condition was classified as early-onset GRAE; otherwise, it was considered late-onset. Multivariate logistic regression analysis was conducted to identify potential factors associated with the timing of GRAE onset. Additionally, the re-operation rates between two surgical approaches—glaucoma valve implantation and trabeculectomy—used for controlling elevated intraocular pressure were compared using the chi-square test.

The study led to the following findings:

  • The study included 125 eyes from 94 patients who developed glaucoma-related adverse events following pediatric cataract surgery.
  • Among the patients, 25 had unilateral cataracts, while 69 had bilateral cataracts (100 eyes).
  • Of the 125 eyes, 63 (50.4%) underwent initial cataract surgery before 6 months, and 97 (77.6%) before 2 years of age.
  • Seventy-six eyes (60.8%) were aphakic, 21 (16.8%) had primary intraocular lens (IOL) implantation, and the remaining 28 (22.4%) had secondary IOL implantation.
  • Sixty-nine out of 104 eyes (66.3%) developed late-onset GRAE.
  • Multivariate analysis revealed that younger age at cataract surgery was associated with early-onset GRAE.
  • Closed angles were observed in 72.1% of eyes before the first anti-glaucomatous surgeries.
  • After trabeculectomy, 50% of eyes required re-operation to control intraocular pressure, compared to 12.1% after glaucoma valve implantation.

“The findings suggest that pediatric cataract surgery performed at an earlier age is associated with a higher likelihood of developing early-onset glaucoma-related adverse events. Additionally, glaucoma valve implantation appears to be the preferred surgical intervention for managing GRAE in these patients,” the researchers concluded.

Reference:

Wu, N., Sun, X. Factors associated with the time of glaucoma-related adverse events onset after pediatric cataract surgery and the preferred anti-glaucomatous surgical selection. Int Ophthalmol 45, 28 (2025). https://doi.org/10.1007/s10792-025-03412-w

Powered by WPeMatico

What is the Potential Role of Injectable Platelet-Rich Fibrin in Dentistry?

Researchers have found in a new research that injectable Platelet-Rich Fibrin (i-PRF) may have a significant role in dentistry, potentially enhancing both soft and hard tissue regeneration. This study was conducted by Unnati S. and colleagues published in the journal JMIR Research Protocols. i-PRF increases the levels of collagen, transforming growth factor β (TGF-β), and PDGF, which makes it a bioactive agent capable of regenerating soft and hard periodontal tissues.

The researchers will search electronically through six major databases: PubMed, Cochrane Library, Google Scholar, Semantic Scholar, Scopus, and Web of Science. Inclusion criteria include only RCTs published in English, which compare i-PRF with other biomaterials for periodontal regeneration. Manual searches will also be carried out through the relevant references. Study selection, data extraction, and risk assessment will be done independently by two reviewers using the Risk of Bias 2 tool.

Key Findings

  • Databases: A comprehensive database search will be conducted for the research.

  • Outcomes of Interest: The criteria for evaluation involve mean differences in clinical measures including:

  • Gingival Recession: Changes after treatment.

  • Probing Pocket Depth: Change following intervention.

  • Clinical Attachment Level: Restoration of periodontal structures.

  • Bone Gain: Increase in bone density at the affected areas.

  • Gingival Width: Soft tissue regeneration results.

  • Timeframe: The synthesis started in October 2023 and will end by December 2025.

  • Statistical Model: The combined effect sizes and 95% CIs will be estimated using a random-effects model.

The planned systematic review will assess clinical measures to determine i-PRF’s place in routine periodontal treatment. i-PRF could revolutionize periodontal therapy by enhancing soft and hard tissue regeneration. This study aims to provide robust evidence for its clinical application, paving the way for improved patient outcomes in dentistry.

Reference:

Shirbhate U, Bajaj P, Wanjari M, Patil M. Role of Injectable Platelet-Rich Fibrin in the Management of Soft and Hard Tissue Periodontal Regeneration in Dentistry: Protocol for a Systematic Review. JMIR Res Protoc. 2025 Jan 23;14:e65137. doi: 10.2196/65137. PMID: 39847766.

Powered by WPeMatico